Selumetinib in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Exclusion Criteria

• •Any prior exposure to mitogen-activated protein kinase kinase (MEK), Ras, or v-raf murine sarcoma 3611 viral oncogene homolog (Raf) inhibitors
• •Patients with any active central nervous system (CNS) involvement by lymphoma are excluded
• •Patients that are taking drugs that alter CYP450 3A4 (or cannot be changed to drugs that do not alter CYP450 3A4) are excluded
• •Cardiac conditions as follows:
• •* Uncontrolled hypertension (blood pressure \[BP\] \>= 150/95 despite optimal therapy)
• •* Heart failure New York Heart Association (NYHA) class II or above
• •* Prior or current cardiomyopathy
• •* Baseline left ventricular ejection fraction (LVEF) =\< 50%
• •* Atrial fibrillation with heart rate \> 100 beats per minute (bpm)
• •* Unstable ischemic heart disease (myocardial infarction \[MI\] within 6 months prior to starting treatment, or angina requiring use of nitrates more than once weekly)
• •* Patients are excluded if there is corrected QT (QTc) interval \> 450 msecs or other factors that increase the risk of QT prolongation or arrhythmic events (e.g., heart failure, hypokalemia, family history of long QT interval syndrome)
• •* Patients are excluded if they are taking any drugs that may significantly prolong the QTc; these drugs are prohibited during the study; if the patient is taking one or more of these medications, they may enroll if all pertinent medications are stopped with the associated "wash out" periods
• •Absolute neutrophil count (ANC) \< 1.5 x 10\^9/L (1500 per mm\^3)
• •Platelets \< 100 x 10\^9/L
• •Hemoglobin (Hgb) \< 8.0 g/dL
• •Serum bilirubin \>= 1.5 x upper limit of normal (ULN)
• •Aspartate aminotransferase (AST/serum glutamic oxaloacetic transaminase \[SGOT\]) or alanine aminotransferase (ALT/serum glutamate pyruvate transaminase \[SGPT\]) \>= 2.5 x ULN (\>= 5 ULN in presence of liver metastases)
• •There should be a minimum of a 1 month wash-out interval from another investigational product to AZD6244 hyd-sulfate dosing start plus recovery from side effects of investigational product
• •There should be a minimum of a 1 month wash-out interval from the end of previous systemic treatment and radiotherapy
• •Patients are excluded if there is a history of a serious medical or psychiatric illness likely to interfere with participation in this clinical study
• •Patients may not have recent history of refractory nausea and vomiting, chronic gastrointestinal diseases (e.g., inflammatory bowel disease), or significant bowel resection that would preclude adequate absorption